Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026
26 patents granted to the 5 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Galectin Therapeutics Inc.’s names, not what it holds today.
Patents granted
26
26 utility, 1976 to Dec 31, 2025
Granted in 2025
1
Against none in 2024 and 2 in 2023
Applications published
35
since 2001, to Dec 31, 2025
Names they are printed under
5
its own name, a former name, a subsidiary
By yearGrantedApplications published
'08'11'12'13'14'15'16'17'18'19'20'21'22'23'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name5 counted
GALECTIN THERAPEUTICS, INC. its own name
US, as the owner printed on each patent
7 publishedGalectin Therapeutics, Inc. its own name
named as the applicant on its applications, in US
13 publishedPro-Pharmaceuticals, Inc. a former name
US, as the owner printed on each patent
8 publishedGALECTIN SCIENCES, LLC a subsidiary
named as the applicant on its applications, in US
7 publishedGalectin Sciences, LLC a subsidiary
US, as the owner printed on each patent
0 published
Newest grantseach row opens the USPTO’s own copy
| Granted | Patent | Title | Field | Owner as printed |
|---|
| Aug 5, 2025 | 12,377,102 | Compounds for the prevention and treatment of medical disorders and uses thereof | Pharmaceuticals | Galectin Sciences, LLC |
| Feb 21, 2023 | 11,583,530 | Compounds for the prevention and treatment of medical disorders and uses thereof | Pharmaceuticals | Galectin Sciences, LLC |
| Feb 14, 2023 | 11,576,924 | Compounds for the prevention and treatment of diseases and the use thereof | Pharmaceuticals | Galectin Sciences, LLC |
| Aug 16, 2022 | 11,413,303 | Methods for treatment of arthritis | Pharmaceuticals | GALECTIN THERAPEUTICS, INC. |
| Oct 13, 2020 | 10,799,525 | Composition of novel carbohydrate drug for treatment of human diseases | Pharmaceuticals | GALECTIN THERAPEUTICS, INC. |
| Aug 18, 2020 | 10,744,154 | Galactose-pronged polysaccharides in a formulation for antifibrotic therapies | Pharmaceuticals | GALECTIN THERAPEUTICS, INC. |
| Sep 24, 2019 | 10,420,793 | Composition of novel carbohydrate drug for treatment of human diseases | Pharmaceuticals | GALECTIN THERAPEUTICS, INC. |
| Sep 3, 2019 | 10,398,778 | Method for enhancing specific immunotherapies in cancer treatment | Pharmaceuticals | GALECTIN THERAPEUTICS, INC. |
| May 22, 2018 | 9,974,802 | Composition of novel carbohydrate drug for treatment of human diseases | Pharmaceuticals | GALECTIN THERAPEUTICS, INC. |
| May 15, 2018 | 9,968,631 | Method for treatment of pulmonary fibrosis | Pharmaceuticals | GALECTIN THERAPEUTICS, INC. |
Newest applications publishedan application is a clue, never a plan
| Published | Application | Title | Field | Owner as printed |
|---|
| Apr 27, 2023 | 2023/0132265 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF DISEASES AND THE USE THEREOF | Pharmaceuticals | GALECTIN SCIENCES, LLC |
| Apr 27, 2023 | 2023/0127345 | SELENOGALACTOSIDE COMPOUNDS FOR THE PREVENTION AND TREATMENT OF DISEASES ASSOCIATED WITH GALECTIN AND THE USE THEREOF | Pharmaceuticals | GALECTIN SCIENCES, LLC |
| Apr 13, 2023 | 2023/0116370 | Compounds for the Prevention and Treatment of Medical Disorders and Uses Thereof | Pharmaceuticals | GALECTIN SCIENCES, LLC · patent 12,377,102 granted from it |
| Jan 5, 2023 | 2023/0000898 | COMPOSITION OF NOVEL CARBOHYDRATE DRUG FOR TREATMENT OF HUMAN DISEASES | Pharmaceuticals | Galectin Therapeutics, Inc. |
| Apr 1, 2021 | 2021/0093656 | Composition of Novel Carbohydrate Drug for Treatment of Human Diseases | Pharmaceuticals | Galectin Therapeutics, Inc. · patent 11,413,303 granted from it |
| Jan 14, 2021 | 2021/0008097 | Compositions Comprising Galactose-Pronged Polysaccharides | Pharmaceuticals | Galectin Therapeutics, Inc. |
| May 21, 2020 | 2020/0155586 | Compounds for the Prevention and Treatment of Diseases and the Use Thereof | Pharmaceuticals | GALECTIN SCIENCES, LLC · patent 11,576,924 granted from it |
| May 14, 2020 | 2020/0147088 | Compounds for the Prevention and Treatment of Medical Disorders and Uses Thereof | Pharmaceuticals | GALECTIN SCIENCES, LLC · patent 11,583,530 granted from it |
| Mar 12, 2020 | 2020/0078390 | Composition of Novel Carbohydrate Drug for Treatment of Human Diseases | Pharmaceuticals | Galectin Therapeutics, Inc. · patent 10,799,525 granted from it |
| Feb 27, 2020 | 2020/0061095 | Compounds for the Treatment of Systemic Insulin Resistance Disorders and the Use Thereof | Pharmaceuticals | GALECTIN SCIENCES, LLC |
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.